Shukra Pharmaceuticals (524632) Q2 25/26 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter and half year ended September 30, 2025, and reviewed business operations.

• Statutory auditors provided an unqualified review opinion on the results.

Financial highlights

• Revenue from operations for Q2 FY26 was ₹587.74 lakhs, up from ₹555.52 lakhs in Q2 FY25.

• Net profit for Q2 FY26 stood at ₹237.81 lakhs, compared to ₹53.89 lakhs in Q2 FY25.

• Total income for H1 FY26 was ₹1,409.08 lakhs, with net profit at ₹340.77 lakhs.

• Earnings per share (EPS) for Q2 FY26 was ₹0.05, up from ₹0.02 in Q2 FY25.

Key financial ratios and metrics

• Gross margin improved due to higher revenue and controlled expenses.

• Equity share capital remained at ₹4,378.79 lakhs.

• Other equity increased to ₹2,201.78 lakhs as of September 30, 2025.